Enterically delivered alginates as prebiotics

Commonly consumed food ingredient with good safety profile Inexpensive in comparison to may current cancer treatments May reduce the progression of polyps to cancer

Epidemiological, animal and cellular evidence supports the hypothesis that iron metabolism plays a central role in the causation of cancer. In particular workers at the University have previously reported that the main proteins implicated in cellular iron transport are modulated during carcinogenesis, notably in colorectal cancer, and that this may promote the development and progression of cancer. Recent work using animal models of colorectal cancer has shown that it is specifically the levels of iron in the intestinal lumen of the colon that is important in promoting cancer rather than systemic levels of iron. This is important as it suggests that a therapeutic strategy to ΓÇ£mop upΓÇØ iron in the colon could be effective at reducing colorectal cancer without the need to induce systemic anaemia. The targeted delivery of chelators such as sodium alginate to the colon offers a real prospect of improving the outcome for colorectal cancer patients

Inventor: TSELEPIS, Chris | IQBAL, Tariq
Priority Number: WO2011051665A1
IPC Current: A61K0031715 | A61P003500
Assignee Applicant: The University of Birmingham
Title: ANTI-CANCER COMPOSITION COMPRISING ALGINATE | COMPOSITION ANTICANCÉREUSE COMPRENANT DE L'ALGINATE
Usefulness: ANTI-CANCER COMPOSITION COMPRISING ALGINATE | COMPOSITION ANTICANCÉREUSE COMPRENANT DE L'ALGINATE
Summary: For the prophylaxis and/or treatment of colorectal cancer in a mammal; and for the selective targeting of the iron chelator to the colon (claimed).
Novelty: Composition useful for prophylaxis and treatment of colorectal cancer in a mammal, and for selective targeting of iron chelator to the colon comprises an iron chelator

Disease Diagnostic/Treatment

Cancer/Tumor

USA